Quick Facts

• Relieves pain following trauma or surgery.
• Manages severe acute pain.
• Reduces fever when other interventions are ineffective.

---

Therapeutic Applications of Баралгин М

The therapeutic utility of Баралгин М (metamizole sodium) primarily centers on the management of pain and the reduction of elevated body temperature (fever). It is often utilized in situations where standard interventions are unsuitable or insufficient to achieve the intended effect.

This medicine is designated for the treatment of pain considered to be acute and severe. This includes the management of pain that may occur after surgical procedures or following injuries and trauma. Its therapeutic profile also includes application for severe pain associated with colic, such as biliary or renal colic, due to its properties that help relieve smooth muscle spasms.

In addition to pain management, the medication is used for the reduction of fever that is persistent or high and does not adequately respond to other available fever-reducing therapies. Its application includes cases of severe acute pain and fever not responding to other treatments. The use of the substance involves a clinical balance between therapeutic benefit and potential hematological safety considerations.

Its action is distinct from conventional non-steroidal anti-inflammatory drugs (NSAIDs), providing a valuable option in specific scenarios for pain and fever control.

The eligibility for using Баралгин М (Metamizole Sodium) is strictly defined by regulatory authorities based on patient history, age, and pre-existing health status.

Absolute Non-Eligibility (Contraindications)

Use is strictly prohibited for individuals with a known history of agranulocytosis caused by pyrazolone derivatives or established diseases of the haematopoietic system. It is also contraindicated in patients with known hypersensitivity to metamizole, certain metabolic disorders (acute intermittent hepatic porphyria or G6PD deficiency), and analgesic-induced bronchial asthma. The medicine must not be used in the presence of undiagnosed acute abdominal pain.

Age and Life Stage Restrictions

Баралгин М is strictly contraindicated for infants under 3 months of age or those with a body weight under 5 kg. Use is absolutely prohibited during the third trimester of pregnancy. For early pregnancy (first and second trimesters), use is restricted and generally avoided. Breastfeeding women must discard milk for a 48-hour period after a single dose, as defined in regulatory labeling.

Conditional Use

Patients with impaired hepatic or renal function and older adults must avoid repeated high doses due to potential alterations in drug clearance, requiring special regulatory caution.

Interactions with other medicines and products

Баралгин М (Metamizole) has documented interactions with other medicinal products and product classes based on both pharmacokinetic (how the body handles the drug) and pharmacodynamic (how the drug affects the body) mechanisms.

Pharmacokinetic Interactions

Metamizole is a moderate to strong inducer of liver enzymes, notably CYP3A4, CYP2B6, and CYP2C19. This enzyme induction can lead to a decrease in the plasma concentration and, potentially, reduced effectiveness of co-administered medicines metabolized by these enzymes. Specific examples include the immunosuppressants Cyclosporine and Tacrolimus. Concomitant use with these agents requires careful monitoring of the immunosuppressant plasma concentration, and dose adjustment or choosing an alternative analgesic may be necessary.

Pharmacodynamic Interactions

Metamizole inhibits the effect of low-dose Acetylsalicylic acid (ASA) on platelet aggregation when taken simultaneously. This interaction is clinically significant in patients with an increased cardiovascular risk who rely on ASA for cardioprotection, and concurrent use should be avoided in this patient group.

Interaction-Related Restrictions

Combination with other non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors is generally avoided due to an increased risk of acute renal and hepatic injury, and a heightened risk of agranulocytosis. Caution is also advised when combining Metamizole with any other medicine that may cause agranulocytosis. If Metamizole is used at high dosages for more than one day, all potential pharmacokinetic and dynamic interactions must be taken into account.

Баралгин М, which contains Metamizole, is an aminopyrine derivative acting as a pro-drug, rapidly hydrolyzing into the primary active metabolite, 4-methylaminoantipyrine (4-MAA), and subsequently to 4-aminoantipyrine (4-AA). The mechanism of action involves multiple pathways within the central nervous system (CNS) and peripheral tissues.

Molecular and Cellular Targets

4-MAA and 4-AA exert their effects primarily through inhibition of prostaglandin synthesis. They act as non-selective inhibitors of cyclooxygenase (COX) enzymes, particularly exhibiting a higher affinity for COX-3, a splice variant predominantly expressed in the CNS (brain and spinal cord). This interaction reduces the formation of prostanoids, such as prostaglandin E2 (PGE2), in the hypothalamus and dorsal horn of the spinal cord.

Downstream Cascades and Systemic Modulation

Inhibition of central PGE2 production modulates the hypothalamic set-point, leading to systemic thermoregulation. The metabolites also interact with other systems: 4-AA is linked to agonist activity at cannabinoid receptor type 1 ( CB1), and 4-MAA's effects involve guanosine 3',5'-cyclic monophosphate (cGMP) activation and opening of ATP-sensitive potassium ( K ATP) channels. The spasmolytic action involves a reduction in inositol phosphate synthesis, which decreases the release of intracellular Ca^2+ in smooth muscle tissue, resulting in a systemic reduction of smooth muscle tone.

Administration Protocol

The parameters for Баралгин М (Metamizole Sodium) include specific administration routes, dose limits, and frequency. The medicine is utilized through Oral, Intravenous (IV), Intramuscular (IM), and Rectal routes, depending on the urgency and clinical setting.

Standard Dosing and Schedule

The administration framework is based on starting with the lowest effective dose. For adults and adolescents over 15 years or 53 kg, the maximum single oral dose is 1,000 mg, with a maximum total daily oral dose of 4,000 mg. The drug may be taken up to four times daily, with a minimum interval of 6 to 8 hours observed between doses. The maximum daily parenteral dose (IV/IM combined) is 5,000 mg. Use is generally designated for short-term management of acute conditions.

Population and Procedural Adjustments

• Pediatric Dosing: Dosage for children up to 14 years is calculated by body weight, with a single dose range of 8 to 16 mg/kg.
• Organ Impairment: Dose adjustments are applied for patients with mild to moderate renal or hepatic impairment.
• Special Procedures: Intravenous administration is performed very slowly as a procedural condition. Furthermore, for infants up to 1 year, injection is restricted to the intramuscular route only.

This administration framework outlines how much, how often, and by what method the medicine is used.

Баралгин М: Recent Clinical Evidence

Research Evidence for Acute Severe Pain

Research, primarily composed of Randomized Controlled Trials and meta-analyses, has explored the use of this medicine in the context of severe, short-term pain, such as postoperative discomfort and pain associated with colic. Studies monitored outcomes related to physical discomfort by measuring changes in pain intensity over short-term assessment periods, typically focusing on the initial 24 hours. The existing evidence is largely limited to this short duration, as follow-up in most trials was brief.

Evidence for the Management of Fever (Antipyresis)

The medicine was evaluated in studies that monitored outcomes related to systemic imbalance (fever). Trials reported patterns related to measured changes in body temperature in both children and adults with persistent fever. Studies involving febrile children described measured temperature changes that were examined alongside those observed with other antipyretic agents. Robust comparative research in general adult populations remains scarce.

Evidence for Use in Acute/Subacute Low Back Pain

Research has explored this medicine in conditions marked by functional limitations, specifically acute or subacute low back pain in adults. These clinical trials monitored patient-reported outcomes describing perceived discomfort and functional activity levels. Studies reported patterns of measured changes in pain intensity over intermediate periods (e.g., two weeks), but long-term effects beyond these study durations are not fully established.

Research Gaps and Limitations

Across all indications, research exploring short-term symptom changes is more frequent than studies examining long-term outcomes. Specific patient groups, including pediatric and critically ill adults, were included in some studies. However, data are still emerging for many other groups where specific health factors are relevant, and research remains insufficient. Key limitations include modest sample sizes in older trials and a lack of comparative evidence for some specific indications.

Common questions about Баралгин М (FAQ)

---

Q: Is Баралгин М considered a pain reliever or an antispasmodic?

Official classifications describe the active ingredient, Metamizole, as primarily an analgesic (pain reliever) and antipyretic (fever reducer). It also possesses spasmolytic properties, which means it can help relax smooth muscle tissue. Therefore, its documented action involves both pain relief and muscle relaxation.

Q: What kind of headache is Баралгин М meant to treat?

The medicine is generally indicated for the treatment of pain. Regulatory documents in various markets specify uses for pain associated with headaches, and in some cases, specifically mention conditions like migraine headache.

Q: How quickly can I expect to notice the effects of Баралгин М?

Official product information defines the timeframe for the medicine's activity in the body. The time it takes for the effects to begin can vary depending on the specific way the medicine is administered (e.g., tablet versus injection).

Q: How long does the effect of Баралгин М typically last?

Regulatory information on the active ingredient’s pharmacokinetics describes the duration of its effect. The typical duration of the pain-relieving action is described as lasting approximately 4 to 6 hours.

Q: Does Баралгин М cause drowsiness or affect driving?

Official safety information lists potential side effects affecting the nervous system, such as drowsiness and fatigue. Information notes that if these effects occur, caution is advised before engaging in activities that require focus, such as operating machinery or driving.

Q: Is Баралгин М similar to Aspirin or Ibuprofen?

While Баралгин М is used for pain relief like ibuprofen and aspirin, it is chemically classified as a pyrazolone derivative and an atypical analgesic. Regulatory documents describe its mechanism of action as distinct from that of conventional non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Can I take Баралгин М if I am taking blood pressure medicine?

Official documents advise caution regarding co-administration with certain blood pressure lowering medicines (antihypertensives), as this combination may affect the blood pressure medicine’s effectiveness. Regulatory materials note that special caution may be relevant for individuals with a history of low blood pressure.

Q: Does Баралгин М interact with antibiotics?

The active metabolites of the medicine are known to induce certain liver enzymes (CYP450). This process can potentially affect the concentration of many co-administered medicines in the body, which includes certain antibiotics. Specific interaction details are available in the official prescribing information.

Q: Are there any known interactions between Баралгин М and herbal supplements?

Regulatory guidance includes the reminder that patients should inform a healthcare provider about the use of any products, including herbal tonics and supplements. These may contain substances that could potentially interact with the active ingredient.

Q: Is there a maximum number of days Баралгин М should be used?

Regulatory documents recommend the use of this medicine for short-term management of acute conditions. In clinical practice, the maximum duration is determined by a healthcare provider based on the acute nature of the condition.

Q: Can Баралгин М be combined with paracetamol?

Official interaction information indicates that the active ingredient may affect the body's processing (excretion rate) of Paracetamol (Acetaminophen). This effect could potentially lead to increased levels of Paracetamol remaining in the body.

Q: What happens if Баралгин М is taken with alcohol?

Regulatory documents explicitly advise that alcohol should not be consumed while using this medicine.

Q: Are there any dietary restrictions while using Баралгин М?

Official product information advises that certain foods can potentially influence how the medicine works in the body. Patients are generally advised to consult with a healthcare professional regarding specific dietary guidance or restrictions.

Q: What is the history of Баралгин М's use?

The active ingredient, Metamizole, has been in use globally for approximately a century. Its availability and authorization status have varied significantly over this time, with regulatory assessments changing across different countries.

Q: Why is Баралгин М sometimes restricted in other countries?

Regulatory bodies in some regions have decided to withhold or withdraw market authorization for the active ingredient. This action is primarily due to the rare, but potentially life-threatening, risk of severe blood disorders, such as agranulocytosis.

Q: Is Баралгин М available over-the-counter or only by prescription?

The availability of this medicine varies significantly across different countries. In some regions, it is available over-the-counter (OTC), while in others, it is strictly classified as a prescription-only medicine.

Q: Is it true that Баралгин М has been removed from some markets?

Yes, regulatory authorities in some regions, including the United States, the United Kingdom, and certain European Union member countries, have decided to withdraw or withhold market authorization for the active ingredient. This decision was made due to safety concerns related to severe adverse reactions.

Q: Can Баралгин М be used to treat dental pain?

The medicine is indicated for the treatment of various acute pains. In certain markets, its official indications include the management of general acute discomfort like toothaches and pain following surgical procedures or injury.

Q: Does Баралгин М have any risk of dependence or addiction?

The medicine is officially classified as a non-opioid analgesic, meaning it does not carry the same risk of dependence as opioid medicines. While there are limited reports in medical literature describing cases of misuse, its non-opioid nature is a key classification.

Q: Why is the active ingredient in Баралгин М sometimes controversial?

The controversy surrounding the active ingredient relates to the rare, but potentially life-threatening, risk of severe adverse events. The primary concern cited by regulatory bodies is the blood disorder known as agranulocytosis.

Q: Is Баралгин М primarily used in Eastern European or other markets?

The use of the active ingredient shows significant geographic variation globally. It remains a widely used and often popular analgesic in several countries in Latin America and Europe, including Eastern European regions, where it maintains regulatory approval.

Q: Can Баралгин М be used for menstrual cramps?

The medicine is officially used for acute pain associated with smooth muscle spasms (spasmolytic action) and conditions like colic. Its established mechanism of action addresses the type of discomfort associated with smooth muscle cramping.

Q: What are the signs of taking too much Баралгин М?

In cases of accidental intake exceeding the recommended amount, seeking immediate medical attention is a regulatory recommendation. Taking too much medicine can potentially lead to symptoms such as nausea, vomiting, stomach pain, and serious damage to the kidneys or liver, as listed in official documents.

Q: Is Баралгин М available as a generic medicine?

The active ingredient is Metamizole Sodium (also known as Dipyrone), which is the generic name of the substance. Medicines containing this active ingredient are widely available under various brand names, including generic formulations, depending on the country.

Q: What type of pain is Баралгин М primarily indicated for?

Official regulatory documents primarily indicate the medicine for the treatment of acute severe pain following injury or surgery, pain associated with colic, tumor-related pain, and high fever that has not responded to other measures.

Q: How does the drug's purpose relate to colic pain?

The active ingredients in the medicine possess a spasmolytic effect, meaning they can relax the smooth muscles in the body. This specific action is beneficial for relieving the painful spasms associated with conditions such as colic.

Q: Are there specific symptoms that require immediate medical attention while using Баралгин М?

Yes, regulatory documents list symptoms that may signal a serious adverse reaction. These include signs of a severe allergic reaction (e.g., rash, swelling of the face/throat, difficulty breathing) or early signs of blood disorders (e.g., unexplained fever, chills, sore throat, or weakness). Immediate medical attention is advised in official materials if these symptoms occur.

Official Storage and Disposal Requirements

Official regulatory documentation defines mandatory conditions for storing Metamizole Sodium (Баралгин М) to maintain its quality and approved shelf life.

Storage and Handling Requirement	Regulatory Specification
Maximum Temperature	Must generally not exceed 25 C
Prohibited Environment	Do not store in the freezer
Protection from Light	Must be protected from light
Packaging Rule	Store the product in the original package

Maintaining the required temperature and light protection is essential for ensuring the approved shelf life of the product. When the medicine, including any remaining waste materials, is no longer needed, it must be disposed of according to local regulatory requirements for pharmaceutical waste.